This short episode will address some of the trends shaping the future of healthcare:
- agentic AI,
- Longevity efforts,
- Uncertain policy in light of the current US government.
You will hear from Daniel Kraft - founder of NextMed Health - a unique interdisciplinary community dedicated to catalyzing and accelerating the arrival of a new, human-centric, technology-enabled health age.
NextMed Health is a very special event, focused on updates in biotech, policy, convergence of technology and expectations of the future. Daniel shared his views on:
- the expectation that the current US government will not regulate AI and how will this impact healthtech,
- what will be covered around longevity and health span at NextMed ,
- Innovations in the brain-mind-body connection and more.
Expect updates on the conference at:
Newsletter: https://fodh.substack.com/
Youtube: https://www.youtube.com/@facesofdigitalhealth
Linkedin: https://www.linkedin.com/in/tjasazajc/
www.facesofdigitalhealth.com
Related Episodes
How does Cleveland Clinic London invest in AI and healthcare IT?
6% of the hospital budget, EPIC and 100 healthcare IT systems. That's the description of the infrastructure in the Cleveland clinic London. CIO Raihaan Mughal likes to emphasize CEOs are concerned about three things: 1️⃣ Increasing revenue 2️⃣ Reducing cost 3️⃣ Mitigating risk When investing, Cleveland clinic is mindful of Return on investment, return on employee. When it comes to AI, CIO Raihaan ...
HIMSS Global 2025: AI is everywhere
In early March HIMSS Global (https://www.himssconference.com/), the currently biggest global gathering about healthcare IT took place Las Vegas. A few tens of thousands of people visit HIMSS Global every year, it can take 20 minutes to get from one session to another in another building, therefor preparation and planning are key. This year, the key topic seemed to be how are companies embedding AI...
Decoding Cancer: AI, Biomarkers & Precision Medicine
When it comes to cancer, prevalence is increasing and there is still a lot we don't understand about the factors and causes of cancers. Many studies have clearly demonstrated the benefits of biomarker testing for cancer therapy. However, broadly speaking, roughly 30% of cancer patients are eligible for targeted therapies based on their tumor profile. And even when the biomarket is present, roughly...